BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant

• Main Authors: Deepender Kaushik (Author), Simran Dhingra (Author), Madhuri T. Patil (Author), Sakshi Piplani (Author), Varun Khanna (Author), Yoshikazu Honda-Okubo (Author), Lei Li (Author), Johnson Fung (Author), Isaac G. Sakala (Author), Deepak B. Salunke (Author), Nikolai Petrovsky (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Better adjuvants are needed for vaccines against seasonal influenza. TLR7 agonists are potent activators of innate immune responses and thereby may be promising adjuvants. Among the imidazoquinoline compounds, 1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine (BBIQ) was reported to be a highly acti...